[BHIVA/BASHH 2026] aidsmap: Injectable PrEP in Leeds and London: criteria, approval and continuation
![[BHIVA/BASHH 2026] aidsmap: Injectable PrEP in Leeds and London: criteria, approval and continuation](/api/imagekit?u=https%3A%2F%2Fwww.eatg.org%2Fwp-content%2Fuploads%2F2023%2F12%2F1674900.jpg&w=3840&q=75)
The UK government has expanded its rollout of long-acting injectable HIV PrEP to 2,000 people, though access remains limited due to high costs. NHS trusts are currently developing specific criteria to manage the supply and distribution of the treatment.
Why it matters
The high cost of injectable PrEP compared to daily pills creates significant challenges for public health accessibility and resource allocation.
In February this year, the UK government announced that it was expanding NHS England’s initial rollout of long-acting injectable HIV PrEP to 2000 people rather than the 1000 it initially announced last November.
The report objectively outlines the policy, cost comparisons, and the challenges faced by healthcare providers.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in